Report
Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
Journal of Community Hospital Internal Medicine Perspectives, v 8(5), pp 315-316
03 Sep 2018
PMID: 30357044
Abstract
Context: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote weight loss. Commonly reported serious adverse events include increased mycotic urogenital infections, orthostatic hypotension, and normoglycemic ketoacidosis.
Case report: We present a case of a 47-year old man with a history of type 2 diabetes mellitus initiated on the SGLT-2 inhibitor canagliflozin preoperatively before a penile implant, who presented with late postoperative MRSA bacteremia and scrotal abscess requiring implant extraction.
Conclusion: As the SGLT-2 inhibitors are gaining in popularity, prescribers must be aware of the potential adverse genitourinary infectious outcomes. Providers should use caution and avoid initiating SGLT-2 inhibitors in the perioperative setting, and may even consider holding or discontinuing this medication in the setting of impending GU surgery.
Metrics
1 Record Views
Details
- Title
- Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
- Creators
- Stephen Melnick - Reading HospitalPriya Rajagopalan - Reading HospitalTheresa Lynn - Reading HospitalAnthony Donato - Reading Hospital
- Publication Details
- Journal of Community Hospital Internal Medicine Perspectives, v 8(5), pp 315-316
- Publisher
- Taylor & Francis
- Number of pages
- 2
- Resource Type
- Report
- Language
- English
- Academic Unit
- Medicine (Graduate); General Internal Medicine
- Web of Science ID
- WOS:000451453600015
- Other Identifier
- 991022161834104721